Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.

Adiwinata R; Tanadi C; Pajala FB; Tandarto K; Stella MM; Tenggara JB; Gunarsa RG; Simadibrata P; Siregar L; Nababan SHH; Sulaiman BS; Hasan I; Lesmana CRA; Sudoyo AW

doi:10.5041/RMMJ.10571

← 뒤로

Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.

1/5 보강

Rambam Maimonides medical journal 2026 Vol.17(1) OA

Adiwinata R, Tanadi C, Pajala FB, Tandarto K, Stella MM, Tenggara JB, Gunarsa RG, Simadibrata P, Siregar L, Nababan SHH, Sulaiman BS, Hasan I, Lesmana CRA, Sudoyo AW

📖 무료 전문 🟢 PMC 전문 PMC12857653 🔓 OA PDF unpaywall · cc-by

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Immunotherapy using immune checkpoint inhibitor (ICI) has been increasingly used in the oncology treatment field.

이 논문을 인용하기

↓ .bib ↓ .ris

APA Adiwinata R, Tanadi C, et al. (2026). Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.. Rambam Maimonides medical journal, 17(1). https://doi.org/10.5041/RMMJ.10571

MLA Adiwinata R, et al.. "Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.." Rambam Maimonides medical journal, vol. 17, no. 1, 2026.

PMID 41605828

DOI 10.5041/RMMJ.10571

Abstract

Immunotherapy using immune checkpoint inhibitor (ICI) has been increasingly used in the oncology treatment field. Although ICIs could help suppress cancer and improve survival rates, it could also lead to certain adverse events, including immune-mediated liver injury caused by ICIs (ILICI). The manifestation of ILICI ranged greatly from asymptomatic disease to liver failure and even death. In this review article, we will discuss the pathogenesis, manifestation, and clinical approach of ILICI.